Torthaí cuardaigh - Adewoye, Adeboye

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study de réir Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Sickle Cell Leg Ulcers: Associations with Haemolysis and SNPs in Klotho, TEK and Genes of the TGF-β/BMP Pathway: —Sickle Cell Leg Ulcers, Genetics and Haemolysis— de réir Nolan, Vikki G., Adewoye, Adeboye, Baldwin, Clinton, Wang, Ling, Ma, Qianli, Wyszynski, Diego F., Farrell, John J., Sebastiani, Paola, Farrer, Lindsay A., Steinberg, Martin H.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer de réir De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Sickle Cell Vaso-occlusive Crisis Induces the Release of Circulating Serum Heat Shock Protein-70 de réir Adewoye, Adeboye H., Klings, Elizabeth S., Farber, Harrison W., Palaima, Elizabeth, Bausero, Maria A., McMahon, Lillian, Odhiambo, Adam, Surinder, Safaya, Yoder, Mark, Steinberg, Martin H., Asea, Alexzander

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies de réir Kater, Arnon P., Tonino, Sanne H., Spiering, Marjolein, Chamuleau, Martine E. D., Liu, Roberto, Adewoye, Adeboye Henry, Gao, Jie, Dreiling, Lyndah, Xin, Yan, Doorduijn, Jeanette K., Kersten, Marie José

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Evaluation of the CLL-IPI in Relapsed and Refractory Chronic Lymphocytic Leukemia in Idelalisib Phase 3 Trials de réir Soumerai, Jacob D., Ni, Ai, Xing, Guan, Huang, Julie, Furman, Richard R., Jones, Jeffrey, Sharman, Jeffrey P., Hallek, Michael, Adewoye, Adeboye H., Dubowy, Ronald, Dreiling, Lyndah, Zelenetz, Andrew D.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

A network model to predict the risk of death in sickle cell disease de réir Sebastiani, Paola, Nolan, Vikki G., Baldwin, Clinton T., Abad-Grau, Maria M., Wang, Ling, Adewoye, Adeboye H., McMahon, Lillian C., Farrer, Lindsay A., Taylor, James G., Kato, Gregory J., Gladwin, Mark T., Steinberg, Martin H.

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Contro... de réir Zelenetz, Andrew D., Barrientos, Jacqueline C., Brown, Jennifer R., Coiffier, Bertrand, Delgado, Julio, Egyed, Miklós, Ghia, Paolo, Illés, Árpád, Jurczak, Wojciech, Marlton, Paula, Montillo, Marco, Morschhauser, Franck, Pristupa, Alexander S., Robak, Tadeusz, Sharman, Jeff P., Simpson, David, Smolej, Lukáš, Tausch, Eugen, Adewoye, Adeboye H., Dreiling, Lyndah K., Kim, Yeonhee, Stilgenbauer, Stephan, Hillmen, Peter

Faigh an téacs iomlán Faigh an téacs iomlán Faigh an téacs iomlán